 CAMBRIDGE, Mass., Oct. 12, 2021 GLOBE NEWSWIRE -- Sarepta Therapeutics, Inc. Nasdaq:SRPT, the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market and other conditions, 500,000,000 in shares of its common stock in an underwritten public offering. Sarepta also intends to grant the underwriters a 30-day option to purchase up to an additional 75,000,000 in shares of its common stock. 